Kingsville, MD, United States of America

Barbara S Slusher

This inventor holds 83 USPTO granted patents and 23 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Prodrug Development (CPC class 514 75). Top assignees: Guilford Pharmaceuticals, Inc., Johns Hopkins University, Institute of Organic Chemistry and Biochemistry. Active years: 1997-2026.

USPTO Granted Patents = 83 (Patent Applications = 23)

% Patents Active = 88.0

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 20)

Average Co-Inventor Count = 3.3

ph-index = 19

Forward Citations = 1,186(Granted Patents)

Forward Citations (Not Self Cited) = 938(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Baltimore, MD (US) (2016 - 2023)
Kingsville, MD (US) (1997 - 2024)

Company Filing History:

44 out of 98

Guilford Pharmaceuticals, Inc.

patents

35 out of 3,794

Johns Hopkins University

patents

7 out of 50

Institute of Organic Chemistry and Biochemistry

patents

4. 7 out of 37

Ustav Organicke Chemie a Biochemie Av Cr, V.v.i.

patents

5. 2 out of 4

Institute of Organic Chemistry and Biochemistry as Cr V.V.I.

Eisai Corporation of North America

Icahn School of Medicine at Mount Sinai

patents

10. 1 out of 1

Inst of Organic Chem. and Biochemistry as Cr V.v.i

patent

11. 1 out of 1

Ústav Organické Chemie a Biochemie Av {Hacek Over (c)}{hacek Over ( )}R, V.v.i.

patent

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Prodrugs

Glutamine Antagonists

Cancer Imaging

Neurodegenerative Diseases

Sphingomyelinase Inhibitors

PSMA Inhibitors

Thiolactones

Mebendazole Prodrugs

Nanoparticle Delivery

Cognitive Deficits

Inhibitors

D-amino Acid Oxidase

83 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698306 - Bile acid-GCPII inhibitor conjugates to treat inflammatory diseases, including inflammatory bowel disease (IBD) (2026-08-04),

2. 12643846 - Prodrugs of itaconate and methyl itaconate (2026-06-02),

3. 12527758 - Use of itaconate and its derivatives/analogues to induce hair growth (2026-01-20),

4. 12508271 - Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy (2025-12-30),

5. 12496284 - Use of itaconate and its derivatives/analogues to induce hair growth (2025-12-16),

6. 12492160 - Prodrugs of itaconate and methyl itaconate (2025-12-09),

7. 12195450 - Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors (2025-01-14),

8. 12195419 - Glutamine antagonists and uses thereof (2025-01-14),

9. 11932664 - Prodrugs of prostate specific membrane antigen (PSMA) inhibitor (2024-03-19),

10. 11926640 - Prodrugs of glutamine analogs (2024-03-12),

11. 11866394 - Prodrugs of hydroxamate-based GCPII inhibitors (2024-01-09),

12. 11766423 - 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases (2023-09-26),

13. 11759466 - Inhibition of nSMase for the treatment of human immunodeficiency virus infection (2023-09-19),

14. 11759444 - Methods for cancer and immunotherapy using prodrugs of glutamine analogs (2023-09-19),

15. 11712435 - Mebendazole prodrugs with enhanced solubility and oral bioavailability (2023-08-01),

Title: The Innovative Journey of Barbara S. Slusher

Introduction: Barbara S. Slusher, a pioneering inventor hailing from Kingsville, MD, has made significant contributions to the field of innovations and inventions, particularly in the realm of healthcare and pharmaceuticals.

Latest Patents: Barbara S. Slusher holds several patents in the medical field, focusing on novel drug delivery systems and innovative treatment methods for various diseases and conditions.

Career Highlights: With a distinguished career spanning over two decades, Barbara S. Slusher has worked tirelessly to develop groundbreaking solutions that have the potential to revolutionize the healthcare industry. Her innovative approach to drug development has garnered recognition and praise from peers and experts alike.

Collaborations: Throughout her career, Barbara S. Slusher has collaborated with leading researchers, scientists, and medical professionals to bring her inventions to life. Her ability to work effectively in multidisciplinary teams has been instrumental in the success of her projects.

Conclusion: Barbara S. Slusher's unwavering dedication to innovation and her passion for improving healthcare outcomes have solidified her position as a trailblazer in the field of inventions. Her work continues to inspire future generations of inventors and researchers to push the boundaries of what is possible in the world of healthcare innovations.